US pharmaceutical heavyweight Eli Lilly is in preliminary discussions to acquire AtaiBeckley, a biotechnology company specialising in psychedelic-derived therapies, according to a report from Bloomberg. The talks, which are understood to be at an early stage, could represent one of the most significant moves by a major drugmaker into the emerging field of psychedelic medicine.
AtaiBeckley, formed from a merger between Atai Life Sciences and Beckley Psytech, has a pipeline of compounds based on psilocybin and other psychedelic substances, targeting treatment-resistant depression, post-traumatic stress disorder, and anxiety disorders. The potential acquisition underscores a broader shift in pharmaceutical research towards mental health treatments that have historically been stigmatised.
News of the talks emerged after US markets closed on Wednesday, with AtaiBeckley shares surging more than 30% in after-hours trading. The FTSE 100 edged up 0.2% to 8,245 points on Thursday morning, with healthcare stocks among the gainers. Hikma Pharmaceuticals rose 1.1%, while AstraZeneca added 0.6%, reflecting cautious investor optimism about the sector's direction.
For UK investors and pension holders, the deal highlights the growing commercial potential of psychedelic therapies. Many UK pension funds hold significant stakes in large-cap pharmaceutical companies through tracker funds, meaning a successful acquisition could indirectly boost returns. However, analysts at Shore Capital warned that regulatory hurdles remain substantial, with the UK's Medicines and Healthcare products Regulatory Agency yet to approve any psychedelic-based treatment for routine use.
“This is a bet on the future of mental health treatment,” said Dr. Helen Carver, a healthcare analyst at Berenberg. “Eli Lilly’s interest validates the science, but investors should remember that clinical trials and regulatory approvals are years away. It’s a high-risk, high-reward play.” The talks come as the UK government has committed additional funding to mental health research, though no specific policy changes have been announced.